239 related articles for article (PubMed ID: 21756007)
1. Burden of gastro-oesophageal reflux disease in patients with persistent and intense symptoms despite proton pump inhibitor therapy: A post hoc analysis of the 2007 national health and wellness survey.
Toghanian S; Johnson DA; Stålhammar NO; Zerbib F
Clin Drug Investig; 2011 Oct; 31(10):703-15. PubMed ID: 21756007
[TBL] [Abstract][Full Text] [Related]
2. The burden of disrupting gastro-oesophageal reflux disease: a database study in US and European cohorts.
Toghanian S; Wahlqvist P; Johnson DA; Bolge SC; Liljas B
Clin Drug Investig; 2010; 30(3):167-78. PubMed ID: 20155989
[TBL] [Abstract][Full Text] [Related]
3. Cost and burden of gastroesophageal reflux disease among patients with persistent symptoms despite proton pump inhibitor therapy: an observational study in France.
Bruley des Varannes S; Löfman HG; Karlsson M; Wahlqvist P; Ruth M; Furstnau ML; Despiégel N; Stålhammar NO
BMC Gastroenterol; 2013 Feb; 13():39. PubMed ID: 23448382
[TBL] [Abstract][Full Text] [Related]
4. Effects of structured follow-up and of more effective acid inhibitory treatment in the management of GORD patients in a Swedish primary-care setting: a randomized, open-label study.
Ekesbo R; Sjöstedt S; Sörngård H
Clin Drug Investig; 2011; 31(3):181-9. PubMed ID: 21288053
[TBL] [Abstract][Full Text] [Related]
5. Heartburn in patients with gastro-oesophageal reflux disease in Germany and Sweden: a study on patients' burden of disease.
Jones R; Horbach S; Sander P; Rydén-Bergsten T
Pharmacoeconomics; 2003; 21(15):1091-102. PubMed ID: 14596628
[TBL] [Abstract][Full Text] [Related]
6. Relationship between symptom load of gastro-oesophageal reflux disease and health-related quality of life, work productivity, resource utilization and concomitant diseases: survey of a US cohort.
Wahlqvist P; Karlsson M; Johnson D; Carlsson J; Bolge SC; Wallander MA
Aliment Pharmacol Ther; 2008 May; 27(10):960-70. PubMed ID: 18315585
[TBL] [Abstract][Full Text] [Related]
7. Patient selection for therapy reduction after long-term daily proton pump inhibitor treatment for gastro-oesophageal reflux disease: trial and error.
van der Velden AW; de Wit NJ; Quartero AO; Grobbee DE; Numans ME
Digestion; 2013; 87(2):85-90. PubMed ID: 23364219
[TBL] [Abstract][Full Text] [Related]
8. The effectiveness of esomeprazole 40 mg in patients with persistent symptoms of gastro-oesophageal reflux disease following treatment with a full dose proton pump inhibitor.
Jones R; Patrikios T
Int J Clin Pract; 2008 Dec; 62(12):1844-50. PubMed ID: 19166433
[TBL] [Abstract][Full Text] [Related]
9. Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using combined ambulatory impedance-pH monitoring.
Mainie I; Tutuian R; Shay S; Vela M; Zhang X; Sifrim D; Castell DO
Gut; 2006 Oct; 55(10):1398-402. PubMed ID: 16556669
[TBL] [Abstract][Full Text] [Related]
10. Proton pump inhibitor failure in gastro-oesophageal reflux disease: a perspective aided by the Gartner hype cycle.
Heading RC
Clin Med (Lond); 2017 Apr; 17(2):132-136. PubMed ID: 28365622
[TBL] [Abstract][Full Text] [Related]
11. The impact of treatment for gastro-oesophageal reflux disease on health-related quality of life: a literature review.
Prasad M; Rentz AM; Revicki DA
Pharmacoeconomics; 2003; 21(11):769-90. PubMed ID: 12859219
[TBL] [Abstract][Full Text] [Related]
12. Impact of gastro-oesophageal reflux disease on work productivity despite therapy with proton pump inhibitors in Germany.
Gross M; Beckenbauer U; Burkowitz J; Walther H; Brueggenjuergen B
Eur J Med Res; 2010 Mar; 15(3):124-30. PubMed ID: 20452898
[TBL] [Abstract][Full Text] [Related]
13. Patient satisfaction with switching to esomeprazole from existing proton pump inhibitor therapy for gastro-oesophageal reflux disease: an observational, multicentre study.
Hoogendoorn RJ; Groeneveld L; Kwee JA
Clin Drug Investig; 2009; 29(12):803-10. PubMed ID: 19888786
[TBL] [Abstract][Full Text] [Related]
14. A novel reflux inhibitor lesogaberan (AZD3355) as add-on treatment in patients with GORD with persistent reflux symptoms despite proton pump inhibitor therapy: a randomised placebo-controlled trial.
Boeckxstaens GE; Beaumont H; Hatlebakk JG; Silberg DG; Björck K; Karlsson M; Denison H
Gut; 2011 Sep; 60(9):1182-8. PubMed ID: 21402616
[TBL] [Abstract][Full Text] [Related]
15. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease.
van Pinxteren B; Sigterman KE; Bonis P; Lau J; Numans ME
Cochrane Database Syst Rev; 2010 Nov; (11):CD002095. PubMed ID: 21069670
[TBL] [Abstract][Full Text] [Related]
16. Effect of the GABA(B) agonist baclofen in patients with symptoms and duodeno-gastro-oesophageal reflux refractory to proton pump inhibitors.
Koek GH; Sifrim D; Lerut T; Janssens J; Tack J
Gut; 2003 Oct; 52(10):1397-402. PubMed ID: 12970129
[TBL] [Abstract][Full Text] [Related]
17. Temporal trends of Barrett's oesophagus and gastro-oesophageal reflux and related oesophageal cancer over a 10-year period in England and Wales and associated proton pump inhibitor and H2RA prescriptions: a GPRD study.
Alexandropoulou K; van Vlymen J; Reid F; Poullis A; Kang JY
Eur J Gastroenterol Hepatol; 2013 Jan; 25(1):15-21. PubMed ID: 23022985
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic value of potent acid inhibition in gastro-oesophageal reflux disease.
Monés J
Drugs; 2005; 65 Suppl 1():35-42. PubMed ID: 16335856
[TBL] [Abstract][Full Text] [Related]
19. Systematic review: the association between symptomatic response to proton pump inhibitors and health-related quality of life in patients with gastro-oesophageal reflux disease.
Becher A; El-Serag H
Aliment Pharmacol Ther; 2011 Sep; 34(6):618-27. PubMed ID: 21770991
[TBL] [Abstract][Full Text] [Related]
20. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease.
van Pinxteren B; Numans ME; Bonis PA; Lau J
Cochrane Database Syst Rev; 2001; (4):CD002095. PubMed ID: 11687139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
